HCPLive Five - Dermatology Updates at AAD 2025

The 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Floria, remains one of the most prominent in the field of dermatology, offering attendees a chance to view the latest sessions, check out late-breaking data, and connect with colleagues.

This AAD meeting featured hundreds of new abstracts and late-breaking studies, with critical insights being offered regarding emerging drugs in the pipeline, recent findings on different diseases, and updates to management strategies. The HCPLive editorial team reported live from Orlando as part of our on-site coverage, with a wide variety of on-site interviews with study authors and session presenters being posted onto the HCPLive site and social media accounts.

In this iteration of the HCPLive Five series, the team highlights our video interviews, including discussions regarding roflumilast foam 0.3% for scalp and body psoriasis, bempikibart for severe alopecia areata, advocating for equitable care, and other clinical trial results highlighted during AAD 2025.

Findings on Roflumilast Foam 0.3% for Scalp and Body Psoriasis, with Melinda Gooderham, MD

In this video, the editorial team spoke with Melinda Gooderham, MD, medical director at the SKiN Centre for Dermatology, about the notable improvements that her team observed in patient-related outcomes during the phase 3 ARRECTOR trial. The study evaluated roflumilast foam 0.3% in individuals aged ≥12 years with psoriasis of the scalp and body.

Late-Breaking Data on Bempikibart for Severe Alopecia Areata, with Brett King, MD, PhD

During this interview, Brett King, MD, PhD, associate professor of dermatology at the Yale University School of Medicine’s Department of Dermatology, spoke with the team about his investigative team’s late-breaking data on bempikibart for patients with severe alopecia areata. The findings resulted from the SIGNAL-AA phase 2a study on bempikibart, a drug formerly known as ADX-914, highlight the drug’s efficacy in terms of Severity of Alopecia Tool (SALT) scores and other results.

Future Initiatives by the Skin of Color Society in Dermatology, with Nada Elbuluk, MD, MSc

In this interview conducted in Orlando just prior to AAD at the Skin of Color Society (SOCS) Scientific Symposium, Nada Elbuluk, MD, MSc, assistant professor of dermatology for the USC Keck School of Medicine, spoke with the editorial team about her role as newly-elected president of SOCS and about advice for healthcare providers looking to advocate for equitable care within their practices and institutions.

Icotrokinra, Plaque Psoriasis, and ICONIC-LEAD, with Robert Bissonnette, MD

In this video, Robert Bissonnette, MD, chairman of Innovaderm Research in Canada, spoke about his team’s findings from the ICNONIC-LEAD study regarding icotrokinra. Bissonnette noted that the medication could soon play a major role in the dermatology armamentarium for the management of plaque psoriasis.

Late-Breaking Data on Tapinarof Cream for Atopic Dermatitis, with Linda Stein Gold, MD

This interview featured a discussion with Linda Stein Gold, MD, of the Henry Ford Health System, highlights Stein Gold’s team’s recent clinical trial data on once-daily treatment with tapinarof (Vtama) cream 1% for individuals suffering from atopic dermatitis. Stein Gold noted both her team's findings and their significance for dermatologists.

Interested in dermatology? Learn more about the annual Revolutionizing Atopic Dermatitis (RAD) Conference, hosted by HCPLive Dermatology Times, and our CE/CME partner Physicians’ Education Resource.